Research Assistant Professor, Global Health
Free University of Berlin, PhD
Free University of Berlin and Humboldt University, MD
- Office: Johannesburg, South Africa
- Phone: 617-414-1260
- Email: firstname.lastname@example.org
Gesine Meyer-Rath, MD, PhD, is a physician, health economist, and infectious disease modeler with seven years’ experience in economic evaluations of health care interventions. She is Research Assistant Professor of Global Health at the Center for Global Health & Development working on the economics of HIV and antiretroviral treatment (ART) in resource-limited settings. Her focus lies on modeling methods for economic evaluation, including infectious disease modeling and decision analysis, and translating research into recommendations for public policy. Before joining the CGHD, she worked in the Pediatrics Department of Charité University Hospital Berlin and with the World Health Organization, where she helped with the generalized cost-effectiveness analysis of the ChoICE team and, in 2003, the calculation of the cost of WHO’s “3 by 5” program. From 2006 to 2008, she was a research fellow at the Health Policy Unit of the London School of Hygiene and Tropical Medicine (UK) and a visiting researcher at the Reproductive Health and HIV Research Unit of the University of the Witwatersrand in Johannesburg, South Africa. During this time, she developed mathematical models for the analysis of the cost, outcomes, and economic impact of ART provision in mining companies in South Africa and, for UNICEF, of global resource needs for the care of orphans and vulnerable children. She has worked in and trained health economists from four sub-Saharan African countries and has been resident in South Africa since 2006. Dr. Meyer-Rath currently works on modeling the budgetary requirements for national ART and PMTCT programs and on analyzing the cost and outcomes of pediatric ART provision. She holds an MD/PhD from Humboldt University and Free University, Berlin, Germany, and is pursuing a PhD in Health Economics at the London School of Hygiene and Tropical Medicine.
- Costs and Outcomes of HIV/AIDS Treatment and PMTCT in Zambia
- Costs and Outcomes of HIV/AIDS Treatment in South Africa
- Economics and Epidemiology of HIV/AIDS, Tuberculosis, and Non-Communicable Diseases in Africa and Asia
- Epidemiologic Analyses and HIV Treatment Outcomes in South Africa
- Estimating the Future Costs of HIV/AIDS Treatment in South Africa
- INROADS: Innovations Research on HIV/AIDS
- Update of WHO-CHOICE Cost Effectiveness Analysis for Child Health Interventions
HE2RO Policy Brief 7: Technical Support to the South African Government to Improve Financial Management of HIV/ AIDS
Health beneﬁts, costs, and cost-eﬀectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models
The Lancet Global Health. 2014 Jan; 2(1).
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices
BMC Infectious Diseases. 2014 Jan; 14(14).
Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis
PLoS ONE. 2013 Jun; 8(6).
The South African Medical Journal. 2013 Feb; 103(2).
AIDS 2012. 2013 Jan; 14(27):243-250.
Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa
JAIDS. 2013 Jan; 62(3):322-328.
Cost and Resource Use of Patients on Antiretroviral Therapy in the Urban and Semiurban Public Sectors of South Africa
JAIDS. 2012 Nov; 61(3):25-32.
HIV Treatment as Prevention: Modelling the Cost of Antiretroviral Treatment—State of the Art and Future Directions
Plos One. 2012 Jul; 9(7):1-10.
Scaling up Xpert MTB⁄RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa
Tropical Medicine and International Health. 2012 Jun; 00(00):1-10.
PLoS ONE. 2012 May; 7(5):1-11.
The Incremental Cost Of Introducing Xpert® MTB/RIF into the South African National Tuberculosis Programme
Johannesburg, South Africa; Boston, MA: Health Economics and Epidemiology Research Office, Wits Health Consortium, University of the Witwatersrand (HE2RO); 2011 Jul.
Total Cost and Potential Cost Savings of the National Antiretroviral Treatment (ART) Programme in South Africa 2010 to 2017. Abstract 16112
18th International AIDS Conference; 2010 Jul 18; Vienna.
Survival in Care and CD4 Cell Count Gain on First-line ART Depend on Prior CD4 Cell Count and Time on Treatment: Evidence From a Large South African Cohort. Abstract Z-184
17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 Feb 1; San Francisco.
Good Treatment Outcomes among Foreigners Receiving Antiretroviral Therapy in Johannesburg, South Africa
Int J STD AIDS. 2009 Dec; 20(12):858-62.
The Cost Effectiveness of Integrated Care for People Living with HIV Including Antiretroviral Treatment in a Primary Health Care Centre in Bujumbura, Burundi
AIDS Care. 2009 Dec; 21(11):1388-94.
South Afr J HIV Med. 2007 Jun; 8(2):15-16.
South Afr J HIV Med. 2007 Jun; 8(2):52-56.